Willem Joost Lesterhuis

Willem Joost Lesterhuis

Auto-generated profile, based on publicly available information

Willem Joost Lesterhuis

National Centre for Asbestos Related Diseases, Nedlands, Australia

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2004 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CFCarl Figdor
Carl Figdor
IVI Jolanda M de Vries
I Jolanda M de Vries
WLW Joost Lesterhuis
W Joost Lesterhuis
CMCornelis J M Melief
Cornelis J M Melief

30 October 2005 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
IVI Jolanda M de Vries
I Jolanda M de Vries
WLW Joost Lesterhuis
W Joost Lesterhuis
JBJelle O Barentsz
Jelle O Barentsz
PVPauline Verdijk
Pauline Verdijk
JKJ Han van Krieken
J Han van Krieken
CFCarl Figdor
Carl Figdor

29 May 2014 in Clinical Cancer Research
Verified
Journal Article
Closed access
SHStanleyson V. Hato
Stanleyson V. Hato
AKAndrea Khong
Andrea Khong
IVI. Jolanda M. De Vries
I. Jolanda M. De Vries
WLW. Joost Lesterhuis
W. Joost Lesterhuis
The platinum-based drugs cisplatin, carboplatin, and oxaliplatin belong to the most widely used chemotherapeutics in oncology, showing clinical efficacy against many solid tumors. Their main mechanism of action is believed to be the induction of cancer cell apoptosis as a response to their covalent binding to DNA. In recent years, this picture has increased in complexity, based on studies indicating that cellular molecules other than DNA may potentially act as targets, and that part of the antitumor effects of platinum drugs occurs through modulation of the immune system. These immunogenic effects include modulation of STAT signaling; induction of an immunogenic type of cancer cell death through exposure of calreticulin and release of ATP and high-mobility group protein box-1 (HMGB-1); and enhancement of the effector immune response through modulation of programmed death receptor 1-ligand and mannose-6-phosphate receptor expression. Both basic and clinical studies indicate that at least part of the antitumor efficacy of platinum chemotherapeutics may be due to immune potentiating mechanisms. Clinical studies exploiting this novel mechanism of action of these old cancer drugs have been initiated. Here, we review the literature on the immunogenic effects of platinum, summarize the clinical advances using platinum as a cytotoxic compound with immune adjuvant properties, and discuss the limitations to these studies and the gaps in our understanding of the immunologic effects of these drugs. Clin Cancer Res; 20(11); 2831–7. ©2014 AACR.

1 August 2011 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
WLW. Joost Lesterhuis
W. Joost Lesterhuis
JHJohn B. A. G. Haanen
John B. A. G. Haanen
CPCornelis J. A. Punt
Cornelis J. A. Punt

1 August 2011 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
WLW. Joost Lesterhuis
W. Joost Lesterhuis
CPCornelis J.A. Punt
Cornelis J.A. Punt
SHStanleyson V. Hato
Stanleyson V. Hato
DEDagmar Eleveld-Trancikova
Dagmar Eleveld-Trancikova
BJBastiaan J.H. Jansen
Bastiaan J.H. Jansen
IVI. Jolanda M. De Vries
I. Jolanda M. De Vries
Tumor microenvironments feature immune inhibitory mechanisms that prevent T cells from generating effective antitumor immune responses. Therapeutic interventions aimed at disrupting these inhibitory mechanisms have been shown to enhance antitumor immunity, but they lack direct cytotoxic effects. Here, we investigated the effect of cytotoxic cancer chemotherapeutics on immune inhibitory pathways. We observed that exposure to platinum-based chemotherapeutics markedly reduced expression of the T cell inhibitory molecule programmed death receptor-ligand 2 (PD-L2) on both human DCs and human tumor cells. Downregulation of PD-L2 resulted in enhanced antigen-specific proliferation and Th1 cytokine secretion as well as enhanced recognition of tumor cells by T cells. Further analysis revealed that STAT6 controlled downregulation of PD-L2. Consistent with these data, patients with STAT6-expressing head and neck cancer displayed enhanced recurrence-free survival upon treatment with cisplatin-based chemoradiation compared with patients with STAT6-negative tumors, demonstrating the clinical relevance of platinum-induced STAT6 modulation. We therefore conclude that platinum-based anticancer drugs can enhance the immunostimulatory potential of DCs and decrease the immunosuppressive capability of tumor cells. This dual action of platinum compounds may extend their therapeutic application in cancer patients and provides a rationale for their use in combination with immunostimulatory compounds.

29 April 2012 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
EREsdy N. Rozali
Esdy N. Rozali
SHStanleyson V. Hato
Stanleyson V. Hato
BRBruce W. Robinson
Bruce W. Robinson
RLRichard A. Lake
Richard A. Lake
WLW. Joost Lesterhuis
W. Joost Lesterhuis
Inhibitory molecules of the B7/CD28 family play a key role in the induction of immune tolerance in the tumor microenvironment. The programmed death-1 receptor (PD-1), with its ligands PD-L1 and PD-L2, constitutes an important member of these inhibitory pathways. The relevance of the PD-1/PD-L1 pathway in cancer has been extensively studied and therapeutic approaches targeting PD-1 and PD-L1 have been developed and are undergoing human clinical testing. However, PD-L2 has not received as much attention and its role in modulating tumor immunity is less clear. Here, we review the literature on the immunobiology of PD-L2, particularly on its possible roles in cancer-induced immune suppression and we discuss the results of recent studies targeting PD-L2 in cancer.